Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Grisell Ortiz Lasanta

Internal Medicine San Juan, PR Medical Doctor

NPI 1538362918 CMS profile 1232495

998 Ave Munoz Rivera, San Juan, PR 00927

Open in the dashboard

General payments

$4,422

39 records reported · program years 2019–2024

Research payments

$1,993

Paid to them · 13 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,863,323 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Grisell Ortiz Lasanta of San Juan, PR is reported in the CMS Open Payments database as having received $4,422 across 39 general payments and $1,993 in research payments paid to them. Separately, studies naming them as principal investigator received $5,863,323 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 Research $1,805 10
2023 General $199 2
2022 General $119 4
2022 Research $121 2
2021 General $135 3
2020 General $510 11
2019 General $3,458 19
2019 Research $67 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Grisell Ortiz Lasanta
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Grisell Ortiz Lasanta were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Grisell Ortiz Lasanta Internal Medicine median Middle half National median
2019 $3,458 $159 $48–$570 $163
2020 $510 $119 $33–$402 $114
2021 $135 $135 $37–$521 $132
2022 $119 $141 $42–$496 $149
2023 $199 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AstraZeneca UK Limited $3,234 10 payments
  2. Novartis Pharmaceuticals Corporation $376 3 payments
  3. Merck Sharp & Dohme Corporation $234 2 payments
  4. AbbVie, Inc. $151 8 payments
  5. Janssen Pharmaceuticals, Inc $100 6 payments
  6. Allergan Inc. $79 1 payment
  7. Janssen Research & Development, LLC $58 1 payment
  8. Taiho Oncology, Inc. $54 3 payments
  9. Intercept Pharmaceuticals, Inc. $41 1 payment
  10. Genzyme Corporation $31 1 payment
  11. Other $63 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Travel and Lodging $3,135 6 payments
  2. Food and Beverage $1,287 33 payments
Products named General payments · program years 2019–2024
  1. VENCLEXTA $67 3 payments
  2. ERLEADA $46 3 payments
  3. OCALIVA $41 1 payment
  4. IMBRUVICA $41 2 payments
  5. SARCLISA $31 1 payment
  6. Lenvima $22 1 payment
  7. Lonsurf $19 1 payment
  8. XGEVA $18 1 payment
  9. Kyprolis $18 1 payment
  10. DARZALEX $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Regeneron Pharmaceuticals, Inc. $1,805 10 payments
  2. Novo Nordisk AS $121 2 payments
  3. Gilead Sciences, Inc. $67 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

66

Median for Internal Medicine: 777

Drug cost

$1,379

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Omega-3 Acid Ethyl Esters Generic 32 $1,057
Pantoprazole Sodium Generic 19 $204
Famotidine Generic 15 $117

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record